AMENDMENTS TO THE SPECIFICATION

Replace the paragraph beginning at page 33, line 1 with:

Example 2

In vivo Protection Assay

For <u>in vivo</u> protection studies, <u>MHLA-A31</u>* <u>HLA-A31</u>* transgenic mice are immunized with), 1pg, 1ng, 1µg, 1mg or 100 mg of cancer peptide (SEQ.ID NO:4, 5, 14, 25, 34-28, 41, 42, 46 or 47), intravenously at day zero and day 14 before a subcutaneous challenge with 10⁴CAG-3 B16 mouse melanoma cells or intravenous challenge with 5 x 10⁵ CAG-3 B16 mouse melanoma cells. Mice receiving tumor cells subcutaneously are observed twice a week for tumor development and the size determined. Mice receiving tumor cells intravenously are euthanized on day 12 and the number of lung metastases determined as described by Houghton, A.N. 1994 J. Exp. Med. 180: 1-40.

Replace the paragraph beginning at page 33, line 12 with:

Example 3

In vivo Treatment Assay

For <u>in vivo</u> treatment, <u>MHLA-A31</u>* <u>HLA-A31</u>* transgenic mice are challenged with either 1 x 10⁵ or 5 x 10⁵ CAG-3 B16 mouse melanoma cells intravenously in order to establish pulmonary metastases. Mice are subsequently vaccinated with a recombinant virus expressing cancer peptide (SEQ. ID NO: 4, 5, 14, 25, 34-28, 41, 42, 46 or 47) AT 10⁵ PFU/mg body weight. Mice are euthanized on day 12 and the number of pulmonary metastases in vaccinated mice vs. non-vaccinated mice determined.